Pulse Biosciences (Pulse Biosciences) Operating Income : $-44.63 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Pulse Biosciences Operating Income?

Pulse Biosciences's Operating Income for the three months ended in Mar. 2024 was $-10.62 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-44.63 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Pulse Biosciences's Operating Income for the three months ended in Mar. 2024 was $-10.62 Mil. Pulse Biosciences's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Pulse Biosciences's Operating Margin % for the quarter that ended in Mar. 2024 was %.

Pulse Biosciences's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pulse Biosciences's annualized ROC % for the quarter that ended in Mar. 2024 was -247.71%. Pulse Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -493.03%.

Pulse Biosciences Operating Income Historical Data

The historical data trend for Pulse Biosciences's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences Operating Income Chart

Pulse Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Income

Get a 7-Day Free Trial

-47.95

-49.97

-63.01

-58.06

-43.57

Pulse Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Income	Get a 7-Day Free Trial															-9.56	-10.23	-11.25	-12.53	-10.62

Pulse Biosciences Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.63 Mil.

Pulse Biosciences (NAS:PLSE) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pulse Biosciences's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-42.46 * ( 1 - 0% )	/	( (18.083	+	16.199)	/ 2 )
=	-42.46	/	17.141
=	-247.71 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	59.154	-	2.451	-	( 44.365	-	max(0, 6.708	-	45.328	+	44.365	))
=	18.083

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	49.164	-	2.197	-	( 34.885	-	max(0, 5.081	-	35.849	+	34.885	))
=	16.199

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Pulse Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-42.46	/	( ( (8.784 + max(-4.687, 0))	+	(8.44 + max(-3.016, 0)) )	/	2 )
=	-42.46	/	( ( 8.784	+	8.44 )	/	2 )
=	-42.46	/	8.612
=	-493.03 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.963)	-	(2.451	+	0	+	3.199)
=	-4.687

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.964)	-	(2.197	+	0	+	1.783)
=	-3.016

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Pulse Biosciences's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-10.615	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Pulse Biosciences Operating Income Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulse Biosciences (Pulse Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (NAS:PLSE) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

6L8:Germany

Address

3957 Point Eden Way, Hayward, CA, USA, 94545

Website

https://www.pulsebiosciences.com

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Executives

Robert W Duggan	director, 10 percent owner	611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Kevin Patrick Danahy	officer: Chief Commercial Officer	50 TEABERRY LANE, BRAINTREE MA 02184
Mitchell E. Levinson	director	3957 POINT EDEN WAY, HAYWARD CA 94545
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Maky Zanganeh	director	51 ADAM WAY, ATHERTON CA 94027
Sandra A. Gardiner	officer: CFO & EVP Admin. and Finance	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Shelley D Spray	director	C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545
Laureen Debuono	director
Ed Ebbers	officer: EVP & GM, Dermatology	3957 POINT EDEN WAY, HAYWARD CA 94545
Kenneth A Clark	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Fogarty Thomas J M D	director	C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025
Thierry B. Thaure	director	3957 POINT EDEN WAY, HAYWARD CA 94545
Robert J. Greenberg	director	12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Brian B Dow	officer: CFO & SVP Admin. and Finance	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588